Cryptotanshinone inhibits lung cancer invasion via microRNA‑133a/matrix metalloproteinase 14 regulation

Wang,Huijuan; Zhang,Yanshan; Zhang,Yingguo; Liu,Wenling; Wang,Jihong

doi:10.3892/ol.2019.10580

Cryptotanshinone inhibits lung cancer invasion via microRNA‑133a/matrix metalloproteinase 14 regulation

Authors:
- Huijuan Wang
- Yanshan Zhang
- Yingguo Zhang
- Wenling Liu
- Jihong Wang
View Affiliations

Affiliations: Department of Tumor Chemotherapy, Tumor Hospital of Wuwei, Wuwei, Gansu 733000, P.R. China, Department of Thoracic Surgery, Tumor Hospital of Wuwei, Wuwei, Gansu 733000, P.R. China
Published online on: July 5, 2019 https://doi.org/10.3892/ol.2019.10580
Pages: 2554-2559

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cryptotanshinone inhibits the proliferative and colony formation abilities of human non‑small cell lung cancer cells (NSCLCs). The present study reported that signal transducer and activator of transcription 3 is not the only target of cryptotanshinone during the inhibition of human NSCLCs. It was identified that cryptotanshinone upregulates the expression levels of microRNA (miR)‑30d‑5p, miR‑126‑3p, miR‑133a, miR‑338‑3p and miR‑451a, and downregulates miR‑21‑5p, miR‑96‑5p, miR‑182‑5p and miR‑205‑5p. Among these, miR‑133a was the most significantly upregulated. miR‑133a targets and downregulates the expression of matrix metalloproteinase (MMP)14; however, MMP15, MMP16 and MMP24 were determined to be unaffected. This process was identified to be independent of tissue inhibitor of metalloproteinases 2. Cryptotanshinone also suppresses the invasion of human NSCLCs, which may be due to the inhibited expression of MMP14. In conclusion, cryptotanshinone may serve as a potential therapeutic agent in the treatment of lung cancer.

View Figures

View References

1	Korrodi-Gregório L, Soto-Cerrato V, Vitorino R, Fardilha M and Pérez-Tomás R: From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research. PLoS One. 11:e01659732016. View Article : Google Scholar : PubMed/NCBI
2	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
3	Maj E, Filip-Psurska B, Milczarek M, Psurski M, Kutner A and Wietrzyk J: Vitamin D derivatives potentiate the anticancer and anti-angiogenic activity of tyrosine kinase inhibitors in combination with cytostatic drugs in an A549 non-small cell lung cancer model. Int J Oncol. 52:337–366. 2018.PubMed/NCBI
4	Chen W, Lu Y, Chen G and Huang S: Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anticancer Agents Med Chem. 13:979–987. 2013. View Article : Google Scholar : PubMed/NCBI
5	Chen L, Wang HJ, Xie W, Yao Y, Zhang YS and Wang H: Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Mol Med Rep. 9:2447–2452. 2014. View Article : Google Scholar : PubMed/NCBI
6	Lu L, Zhang S, Li C, Zhou C, Li D, Liu P, Huang M and Shen X: Cryptotanshinone inhibits human glioma cell proliferation in vitro and in vivo through SHP-2-dependent inhibition of STAT3 activation. Cell Death Dis. 8:e27672017. View Article : Google Scholar : PubMed/NCBI
7	Shen L and Zhang G, Lou Z, Xu G and Zhang G: Cryptotanshinone enhances the effect of Arsenic trioxide in treating liver cancer cell by inducing apoptosis through downregulating phosphorylated- STAT3 in vitro and in vivo. BMC Complement Altern Med. 17:1062017. View Article : Google Scholar : PubMed/NCBI
8	Macfarlane LA and Murphy PR: MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 11:537–561. 2010. View Article : Google Scholar : PubMed/NCBI
9	Pratap P, Raza ST, Abbas S and Mahdi F: MicroRNA-associated carcinogenesis in lung carcinoma. J Cancer Res Ther. 14:249–254. 2018.PubMed/NCBI
10	Castro D, Moreira M, Gouveia AM, Pozza DH and De Mello RA: MicroRNAs in lung cancer. Oncotarget. 8:81679–81685. 2017. View Article : Google Scholar : PubMed/NCBI
11	Osada H and Takahashi T: let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci. 102:9–17. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kim YH, Lee WK, Lee EB, Son JW, Kim DS and Park JY: Combined Effect of Metastasis-Related MicroRNA, miR-34 and miR-124 Family, Methylation on Prognosis of Non-Small-Cell Lung Cancer. Clin Lung Cancer. 18:e13–e20. 2017. View Article : Google Scholar : PubMed/NCBI
13	Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 47:423–432. 2013. View Article : Google Scholar : PubMed/NCBI
14	Guttilla IK and White BA: Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem. 284:23204–23216. 2009. View Article : Google Scholar : PubMed/NCBI
15	Ortmann RA, Cheng T, Visconti R, Frucht DM and O'Shea JJ: Janus kinases and signal transducers and activators of transcription: Their roles in cytokine signaling, development and immunoregulation. Arthritis Res. 2:16–32. 2000. View Article : Google Scholar : PubMed/NCBI
16	Pastuszak-Lewandoska D, Domańska-Senderowska D, Kordiak J, Antczak A, Czarnecka KH, Migdalska-Sęk M, Nawrot E, Kiszałkiewicz JM and Brzeziańska-Lasota E: Immunoexpression analysis of selected JAK/STAT pathway molecules in patients with non- small-cell lung cancer. Pol Arch Intern Med. 127:758–764. 2017.PubMed/NCBI
17	Zhang Y, Chen L, Li F, Wang H, Yao Y, Shu J and Ying MZ: Cryptotanshinone protects against adriamycin-induced mitochondrial dysfunction in cardiomyocytes. Pharm Biol. 54:237–242. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chiba T, Nishimoto I, Aiso S and Matsuoka M: Neuroprotection against neurodegenerative diseases: Development of a novel hybrid neuroprotective peptide Colivelin. Mol Neurobiol. 35:55–84. 2007. View Article : Google Scholar : PubMed/NCBI
19	Wu W: MicroRNA, Noise, and Gene Expression Regulation. Methods Mol Biol. 1699:91–96. 2018. View Article : Google Scholar : PubMed/NCBI
20	Stankevicius V, Kuodyte K, Schveigert D, Bulotiene D, Paulauskas T, Daniunaite K and Suziedelis K: Gene and miRNA expression profiles of mouse Lewis lung carcinoma LLC1 cells following single or fractionated dose irradiation. Oncol Lett. 13:4190–4200. 2017. View Article : Google Scholar : PubMed/NCBI
21	Tallant C, Marrero A and Gomis-Rüth FX: Matrix metalloproteinases: Fold and function of their catalytic domains. Biochim Biophys Acta. 1803:20–28. 2010. View Article : Google Scholar : PubMed/NCBI
22	Li S, Lu J, Chen Y, Xiong N, Li L, Zhang J, Yang H, Wu C, Zeng H and Liu Y: MCP-1-induced ERK/GSK-3β/Snail signaling facilitates the epithelial-mesenchymal transition and promotes the migration of MCF-7 human breast carcinoma cells. Cell Mol Immunol. 14:621–630. 2017. View Article : Google Scholar : PubMed/NCBI
23	Jabłońska-Trypuć A, Matejczyk M and Rosochacki S: Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs. J Enzyme Inhib Med Chem. 31 (Supp 1):177–183. 2016. View Article : Google Scholar : PubMed/NCBI
24	Chen Q, Jin M, Yang F, Zhu J, Xiao Q and Zhang L: Matrix metalloproteinases: Inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013:9283152013. View Article : Google Scholar : PubMed/NCBI
25	Xu J, Liu XJ, Li L, Zhang SH, Li Y, Gao RJ and Zhen YS: An engineered TIMP2-based and enediyne-integrated fusion protein for targeting MMP-14 shows potent antitumor efficacy. Oncotarget. 6:26322–26334. 2015. View Article : Google Scholar : PubMed/NCBI
26	Prideaux M, Staines KA, Jones ER, Riley GP, Pitsillides AA and Farquharson C: MMP and TIMP temporal gene expression during osteocytogenesis. Gene Expr Patterns. 18:29–36. 2015. View Article : Google Scholar : PubMed/NCBI
27	Xu M and Wang YZ: miR 133a suppresses cell proliferation, migration and invasion in human lung cancer by targeting MMP 14. Oncol Rep. 30:1398–1404. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zhang Y, Yao Y, Wang H, Guo Y, Zhang H and Chen L: Effects of salidroside on glioma formation and growth inhibition together with improvement of tumor microenvironment. Chin J Cancer Res. 25:520–526. 2013.PubMed/NCBI
29	Yao Y, Liu S, Wang Y, Yuan W, Ding X, Cheng T, Shen Q and Gu J: Suppression of cytochrome P450 reductase expression promotes astrocytosis in subventricular zone of adult mice. Neurosci Lett. 548:84–89. 2013. View Article : Google Scholar : PubMed/NCBI
30	Guan X: Cancer metastases: Challenges and opportunities. Acta Pharm Sin B. 5:402–418. 2015. View Article : Google Scholar : PubMed/NCBI
31	Perlikos F, Harrington KJ and Syrigos KN: Key molecular mechanisms in lung cancer invasion and metastasis: A comprehensive review. Crit Rev Oncol Hematol. 87:1–11. 2013. View Article : Google Scholar : PubMed/NCBI
32	Pawelek JM and Chakraborty AK: The cancer cell - leukocyte fusion theory of metastasis. Adv Cancer Res. 101:397–444. 2008. View Article : Google Scholar : PubMed/NCBI